Stock DNA
Pharmaceuticals & Biotechnology
CNY 28,227 Million (Large Cap)
65.00
NA
1.07%
0.22
7.32%
6.68
Revenue and Profits:
Net Sales:
1,299 Million
(Quarterly Results - Sep 2025)
Net Profit:
166 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
40.57%
0%
40.57%
6 Months
33.8%
0%
33.8%
1 Year
55.52%
0%
55.52%
2 Years
98.28%
0%
98.28%
3 Years
203.53%
0%
203.53%
4 Years
112.56%
0%
112.56%
5 Years
93.64%
0%
93.64%
Haisco Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.89%
EBIT Growth (5y)
-12.72%
EBIT to Interest (avg)
4.76
Debt to EBITDA (avg)
2.08
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
0.59
Tax Ratio
0.70%
Dividend Payout Ratio
117.53%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.05%
ROE (avg)
12.23%
Valuation key factors
Factor
Value
P/E Ratio
65
Industry P/E
Price to Book Value
6.94
EV to EBIT
177.88
EV to EBITDA
68.22
EV to Capital Employed
5.83
EV to Sales
7.29
PEG Ratio
NA
Dividend Yield
1.07%
ROCE (Latest)
3.28%
ROE (Latest)
10.63%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
1,299.30
1,064.60
22.05%
Operating Profit (PBDIT) excl Other Income
181.00
194.10
-6.75%
Interest
8.10
10.60
-23.58%
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
166.50
289.00
-42.39%
Operating Profit Margin (Excl OI)
139.30%
120.00%
1.93%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 22.05% vs 4.97% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is -42.39% vs 123.17% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
3,689.10
3,321.20
11.08%
Operating Profit (PBDIT) excl Other Income
406.60
529.20
-23.17%
Interest
38.20
42.70
-10.54%
Exceptional Items
0.20
-1.80
111.11%
Consolidate Net Profit
466.20
295.60
57.71%
Operating Profit Margin (Excl OI)
41.20%
92.30%
-5.11%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 11.08% vs 10.93% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 57.71% vs -24.53% in Dec 2023
About Haisco Pharmaceutical Group Co., Ltd. 
Haisco Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






